全文获取类型
收费全文 | 67031篇 |
免费 | 5877篇 |
国内免费 | 1289篇 |
专业分类
耳鼻咽喉 | 441篇 |
儿科学 | 3581篇 |
妇产科学 | 1038篇 |
基础医学 | 6997篇 |
口腔科学 | 1066篇 |
临床医学 | 9381篇 |
内科学 | 10875篇 |
皮肤病学 | 792篇 |
神经病学 | 1289篇 |
特种医学 | 1362篇 |
外国民族医学 | 1篇 |
外科学 | 6782篇 |
综合类 | 10067篇 |
现状与发展 | 13篇 |
预防医学 | 11815篇 |
眼科学 | 312篇 |
药学 | 5603篇 |
76篇 | |
中国医学 | 1445篇 |
肿瘤学 | 1261篇 |
出版年
2024年 | 50篇 |
2023年 | 1183篇 |
2022年 | 1747篇 |
2021年 | 3467篇 |
2020年 | 3467篇 |
2019年 | 2486篇 |
2018年 | 2386篇 |
2017年 | 2428篇 |
2016年 | 2647篇 |
2015年 | 2730篇 |
2014年 | 4412篇 |
2013年 | 5142篇 |
2012年 | 4298篇 |
2011年 | 4428篇 |
2010年 | 3247篇 |
2009年 | 3040篇 |
2008年 | 2804篇 |
2007年 | 2997篇 |
2006年 | 2952篇 |
2005年 | 2624篇 |
2004年 | 2369篇 |
2003年 | 2256篇 |
2002年 | 1303篇 |
2001年 | 1210篇 |
2000年 | 964篇 |
1999年 | 888篇 |
1998年 | 681篇 |
1997年 | 619篇 |
1996年 | 549篇 |
1995年 | 592篇 |
1994年 | 545篇 |
1993年 | 476篇 |
1992年 | 453篇 |
1991年 | 399篇 |
1990年 | 306篇 |
1989年 | 310篇 |
1988年 | 258篇 |
1987年 | 222篇 |
1986年 | 174篇 |
1985年 | 239篇 |
1984年 | 157篇 |
1983年 | 110篇 |
1982年 | 124篇 |
1981年 | 105篇 |
1980年 | 70篇 |
1979年 | 63篇 |
1978年 | 53篇 |
1977年 | 43篇 |
1976年 | 48篇 |
1975年 | 22篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
目的通过信息化随访方式干预慢性乙型病毒性肝炎患者,对比分析其对患者疾病及用药依从性影响。方法收集2014年10月至2017年10月惠州市第六人民医院门诊及住院部诊断为慢性乙型病毒性肝炎、乙肝肝硬化患者,剔除不符合纳入条件患者,共纳入符合条件患者264例,有42例合并肝硬化。对纳入患者采取分层随机抽样方法进行分组,最终微信+电话随访组87例,电话随访组88例,对照组89例。随访并对比三组在2年后肝功能、肝硬化人数及停用恩替卡韦时间等不同差异。结果随访年后三组在失访人数上差异存在统计学意义,其中A组与B组2年后两组在ALT(Z=-3.218,P=0.02)、AST(Z=-2.749,P=0.03)、Alb(Z=1.746,P=0.04)、乙肝病毒DNA(Z=-3.231,P=0.02)指标差异具有统计学意义,而TBil、FIB-4指数、APRI、γ-GT指标差异无统计学意义。A组与C组2年后对比结果显示,两组在ALT(Z=-11.089,P<0.001)、AST(Z=-9.247,P=0.01)、TBil(Z=-7.623,P=0.01)、APRI(Z=-4.834,P=0.01)、γ-GT(Z=-2.867,P=0.03)、Alb(Z=3.187,P=0.02)、乙肝病毒DNA(Z=-10.078,P<0.001)指标差异具有统计学意义,而FIB-4指数指标差异无统计学意义。B组与C组2年后两组对比结果显示,两组在ALT(Z=-1.275,P=0.04)、AST(Z=-2.045,P=0.03)、TBil(Z=-3.762,P=0.02)、APRI(Z=-1.461,P=0.04)、γ-GT(Z=-2.254,P=0.03)、乙肝病毒DNA(Z=-1.782,P=0.04)指标差异具有统计学意义,而Alb、FIB-4指数指标差异无统计学意义。随访2年后A组肝硬化人数为12人,B组为16人,C组为24人。A组与B组(χ2=0.945,P=0.408)、B组与C组肝硬化人数(χ2=2.741,P=0.103)差异无统计学意义,而A、C两组肝硬化人数差异有统计学意义(χ2=6.843,P=0.013)。在2年时间内,A组有15例患者暂停使用恩替卡韦,B组有28例,C组有61例,三组停用恩替卡韦人数差异有统计学意义(χ2=25.061,P<0.001),通过Kaplan-meier分析,结果显示A组使用恩替卡韦时间长于B组(83.0%vs 68.5%,χ2=5.754,P=0.016)及C组(83.0%vs 33.7%,χ2=61.601,P<0.001),而B组使用时间长于C组(63.5%vs 33.7%,χ2=32.451,P<0.001)。结论通过对患者强化信息化干预,可以使患者服用抗乙肝病毒药物依从性提高,降低患者肝功能异常发生及肝硬化发病率。 相似文献
42.
43.
44.
45.
46.
47.
《Vaccine》2022,40(33):4889-4896
BackgroundDuring the COVID-19 pandemic, the number of hepatitis B virus (HBV) vaccinations among men who have sex with men (MSM) has been considerably lower than before the pandemic. Moreover, less frequent HBV testing and a reduction in numbers of sex partners have been reported. We assessed the impact of these COVID-19-related changes on HBV transmission among MSM in the Netherlands.MethodsWe estimated the changes in sexual activity, HBV testing, and HBV vaccination among MSM during the pandemic from Dutch data. We used a deterministic compartmental model and investigated scenarios with small or large declines in sexual activity, testing, and vaccination for the current phase of the pandemic (without available data). We examined the increase in HBV vaccinations needed to prevent further increase in HBV incidence.ResultsWith a decrease in numbers of sex partners of 15–25% during the first lockdown and 5% during the second lockdown, we found a decline of 6.6% in HBV incidence in 2020, despite a >70% reduction in HBV testing and vaccination during the first lockdown. With numbers of sex partners rebounding close to pre-pandemic level in 2021, and a reduction of 15% in testing and 30% in vaccination in 2021, we found an increase of 1.4% in incidence in 2021 and 3.1% in 2026. With these changes, an increase of ≥60% in HBV vaccinations in 2022 would be needed to bring the HBV incidence in 2023 back to the level that it would have had if the COVID-19-related changes had not occurred.ConclusionsDespite reductions in sexual activity during the COVID-19 pandemic, the decrease in HBV vaccinations may result in a small increase in HBV incidence after 2021, which may persist for years. It is important to restore the vaccination level and limit further increase in HBV transmission among MSM. 相似文献
48.
49.
50.
Farrukh Ahmad 《World Journal of Critical Care Medicine》2022,11(4):228-235
The cholinergic anti-inflammatory pathway (CAP) refers to the anti-inflammatory effects mediated by the parasympathetic nervous system. Existence of this path way was first demonstrated when acetylcholinesterase inhibitors showed benefits in animal models of sepsis. CAP functions via the vagus nerve. The systemic anti-inflammatory effects of CAP converges on the α7 nicotinic acetylcholine receptor on splenic macrophages, leading to suppression of pro-inflammatory cytokines and simultaneous stimulation of anti-inflammatory cytokines, including interleukin 10. CAP offers a novel mechanism to mitigate inflammation. Electrical vagal nerve stimulation has shown benefits in patients suffering from rheumatoid arthritis. Direct agonists like nicotine and GTS-1 have also demonstrated anti-inflammatory properties in models of sepsis and acute respiratory distress syndrome, as have acetylcholinesterase inhibitors like Galantamine and Physostigmine. Experience with coronavirus disease 2019 (COVID-19) induced acute respiratory distress syndrome indicates that immunomodulators have a protective role in patient outcomes. Dexamethasone is the only medication currently in use that has shown to improve clinical outcomes. This is likely due to the suppression of what is referred to as a cytokine storm, which is implicated in the lethality of viral pneumonia. Nicotine transdermal patch activates CAP and harvests its anti-inflammatory potential by means of an easily administered depot delivery mechanism. It could prove to be a promising, safe and inexpensive additional tool in the currently limited armamentarium at our disposal for management of COVID-19 induced acute hypoxic respiratory failure. 相似文献